Trabectedin and Irinotecan for Refractory Pediatric Sarcomas

Sponsor
Technical University of Munich
Study ID
NCT02509234
Status
Unknown

Conditions

  • Recurrent Childhood Soft Tissue Sarcoma
  • Recurrent Ewing Sarcoma
  • Recurrent Rhabdomyosarcoma

Eligibility Criteria

Sex
ALL
Age
10 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the study is to evaluate patients with refractory childhood sarcomas, who have been treated with a combination therapy of trabectedin and irinotecan (within compassionate use), to determine, if this is a promising treatment option with acceptable toxicity and if the results warrant a prospective study.

Key Dates

Start date
Feb 28, 2014
Status verified
Jul 2015
Primary completion
Jul 31, 2016
Completion
Jul 31, 2017

Study Design

Enrollment
30 participants (estimated)

Primary Outcome Measure

Toxicity during therapy [ Time Frame: As long as patient is undergoing therapy/ 6 months ]

Related Studies